Compare Goldman Sachs Group Inc (GS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Mesoblast Limited — how do they compare? Goldman Sachs Group Inc trades at $1,036.76 (market cap $301.19B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Goldman Sachs Group Inc is far larger — about 136.3× Mesoblast Limited's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GS | MESO | |
|---|---|---|
Market Cap | $301.19B | $2.21B |
Volume | 2,592,735 | — |
Sector | Financials | Technology |
52-Week High | $1.15K | $20.96 |
52-Week Low | $715.95 | $12.88 |
Dividend Yield | 1.93% | — |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.
The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
